152 related articles for article (PubMed ID: 19581734)
1. Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2009 Jul; 10(4):357-60. PubMed ID: 19581734
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics in pancreatic cancer.
Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):359-62. PubMed ID: 23846927
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer: translating lessons from mouse models.
Strimpakos AS; Hoimes C; Saif MW
JOP; 2009 Mar; 10(2):98-103. PubMed ID: 19287100
[TBL] [Abstract][Full Text] [Related]
5. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
6. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Xu X; Strimpakos AS; Saif MW
JOP; 2011 Jul; 12(4):325-9. PubMed ID: 21737888
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.
Harris M; Bhuvaneshwar K; Natarajan T; Sheahan L; Wang D; Tadesse MG; Shoulson I; Filice R; Steadman K; Pishvaian MJ; Madhavan S; Deeken J
Pharmacogenet Genomics; 2014 Feb; 24(2):81-93. PubMed ID: 24401833
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merika E; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Saif MW
JOP; 2009 Jul; 10(4):373-7. PubMed ID: 19581737
[TBL] [Abstract][Full Text] [Related]
12. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Maréchal R; Van Laethem JL
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
[TBL] [Abstract][Full Text] [Related]
13. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Saif MW
JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
[TBL] [Abstract][Full Text] [Related]
15. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Danesi R; Altavilla G; Giovannetti E; Rosell R
Pharmacogenomics; 2009 Jan; 10(1):69-80. PubMed ID: 19102717
[TBL] [Abstract][Full Text] [Related]
17. Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Saif MW
JOP; 2008 Jul; 9(4):398-402. PubMed ID: 18648129
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Ueno H; Kiyosawa K; Kaniwa N
Br J Cancer; 2007 Jul; 97(2):145-51. PubMed ID: 17595663
[TBL] [Abstract][Full Text] [Related]
19. Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Makrilia N; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):351-4. PubMed ID: 21737894
[TBL] [Abstract][Full Text] [Related]
20. Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2010 Mar; 11(2):124-7. PubMed ID: 20208318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
